���构特征与受体作用机制 — Complete Guide

By Editorial Desk · published 2026-06-14 · last reviewed 2026-07-28 · Guide

The short version of GLP-1 fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-07-28. Anything still debated is marked as such rather than presented as settled.

结构特征与受体作用机制

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

Storage, Handling, and Analytical Verification

Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.

Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.

Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.

Semaglutide at a glance

Mechanism and Pharmacological Class

The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.

Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.

Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.

Related pages on this site

• Simple primer
• Smart comparison
• Verified notes
• Adaptive comparison
• Reliable dataset
• Regional casebook
• Balanced playbook
• Standard briefing

Molecular Background and Drug Class

Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.

Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.

Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.

Semaglutide Structure and Receptor Mechanism

Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.

Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.

Background from the literature

Interestingly, relocalization of eIF4E from the nucleus to the cytoplasm correlated with clinical remissions indicative of the relevance of its nuclear activities to disease progression. Subsequent ribavirin trials in AML in combination with antileukemic drugs again showed objective clinical responses including remissions and molecular targeting of eIF4E. Clinical responses correlated with reduced nuclear eIF4E and clinical relapse with re-emergence of eIF4E nuclear eIF4E and its RNA export activity in these AML studies. Other studies used ribavirin in combination showed similar promising results in head and neck cancer. Ribavirin impairs all of the activities of eIF4E examined to date (splicing, capping, RNA export and translation). Thus, eIF4E has been successfully therapeutically targetable in humans; however drug resistance to ribavirin is an emergent problem to long term disease control. eIF4E has also been targeted by antisense oligonucleotides which were very potent in mouse models of prostate cancer, but in monotherapy trials in humans did not provide clinical benefit likely due to the inefficiency of reducing eIF4E levels in humans compared to mice. Recent improvements in nanoparticle delivery may improve this strategy. There is also an allosteric inhibitor of eIF4E which binds between the cap-binding site and the dorsal surface that is used experimentally.

=== Basal === Kalra has remained updated with advancements in insulin therapy and has authored several articles on the evolution of basal insulins and their patient-centred use in various clinical settings. He has also written on the use of basal insulin in special populations such as paediatric groups and pregnant women. His research also includes strategies for intensifying basal insulin therapy and optimising injection techniques. In addition to work on type 2 diabetes, Kalra has written extensively on insulin use in type 1 diabetes.

== Bioinformatics for proteomics (proteome informatics) == Much proteomics data is collected with the help of high throughput technologies such as mass spectrometry and microarray. It would often take weeks or months to analyze the data and perform comparisons by hand. For this reason, biologists and chemists are collaborating with computer scientists and mathematicians to create programs and data pipelines to computationally analyze the protein data. Using bioinformatics techniques, researchers are capable of faster analysis and data storage. A good place to find lists of current programs and databases is on the ExPASy bioinformatics resource portal. The applications of bioinformatics-based proteomics include medicine, disease diagnosis, biomarker identification, and many more.

It was the only instrument in use around 1930, but it was not widely accepted in medical circles. Treatment of acne with ultraviolet radiation is still controversial. Although UV radiation can have an antibacterial effect, it can also induce proliferative hyperkeratosis. This can lead to the formation of comedones ("blackheads"). Phototoxic effects may also occur. In addition, it is carcinogenic and promotes skin aging. UV therapy is increasingly being abandoned in favor of photodynamic therapy.

Undecaprenyl phosphate will attack the UDP-MurNAc penta, creating a PP-MurNac penta, which is now a lipid (lipid I). EC 2.7.8.13 by MraY. UDP-GlcNAc is then transported to MurNAc, creating Lipid-PP-MurNAc penta-GlcNAc (lipid II), a disaccharide, also a precursor to peptidoglycan. EC 2.4.1.227 by MurG. Lipid II is transported across the membrane by flippase (MurJ), a discovery made in 2014 after decades of searching. Once it is there, it is added to the growing glycan chain by the enzyme peptidoglycan glycosyltransferase (GTase, EC 2.4.1.129). This reaction is known as transglycosylation. In the reaction, the hydroxyl group of the GlcNAc will attach to the MurNAc in the glycan, which will displace the lipid-PP from the glycan chain. In a final step, the DD-transpeptidase (TPase, EC 3.4.16.4) crosslinks individual glycan chains. This protein is also known as the penicillin-binding protein. Some versions of the enzyme also performs the glycosyltransferase function, while others leave the job to a separate enzyme.

Sources: en.wikipedia.org

Reference notes

=== Human serum prolidase === Two 493 amino acid chains construct serum prolidase, held together with C2 symmetry. This C2 symmetry refers to the molecule's two-fold rotational symmetry without mirror symmetry. Simply put, if serum prolidase were to be rotated at a 180º angle, it would look the same, however, it does not look the same in a mirror image. Furthermore, this structure has two domains: the N-terminal domain and the C-terminal domain, the latter of which carries the active site in the amino acid residues 185-493. The active site is the area on the enzyme to which the substrate binds and catalysis occurs. This C-terminal domain has the ability to covalently bond to other prolidase enzymes to create a tetramer through disulfide bonds. This domain performs a "pita-bread" fold, consisting of a bimetallic active center held together by two ɑ-helices and one antiparallel β-sheet. Prolidase enzyme is considered homodimeric, meaning it is formed by two identical polypeptide chains. There are both hydrophilic and hydrophobic residues in this enzyme, distributed evenly throughout. Manganese ions (Mn2+) are utilized by serum prolidase as co-factors. Research into the crystal structure has found that two Mn2+ ions are required for the catalytic activity of this enzyme. This requirement leads to prolidase being deemed a metal-activated peptidase, a term used to describe enzymes that catalyze the hydrolysis reaction changing peptides into amino acids having increased ability through the existence of metal ions.

==== Initial loans ==== Townsend entered the senior Tottenham team under manager Harry Redknapp. In August 2009, he went on a month's loan to League One club Leyton Orient, extended at the end of the month to the end of December, after which he returned to Tottenham. In 26 appearances for Orient, Townsend scored twice, including a "great goal" in a 3–3 draw against Yeovil, passing three opposing players with a run that began in his own half, leading the opposition manager to lament that his players had not been more ruthless and taken him down with a professional foul. Having not yet made his Tottenham debut, on 14 January 2010, Townsend was again taken on loan by a League One club, Milton Keynes Dons, until the end of the season, although he was recalled after just two months due to injuries. In nine matches for the Dons he had scored twice. The season ended without Townsend having made his debut for Tottenham. On 12 August 2010, Townsend signed another season-long loan, moving up to the Championship level with Ipswich Town, but this was terminated on 20 December, as Redknapp believed he had not been playing regularly enough. He had played 16 times, scoring once.

=== Immunoglobulins, complement and fibrinogen === Immunoglobulins (IgM, IgA), complement (C3), and fibrinogen have been found in blood vessel walls of patients with NL. Both Immunoglobulin and C3 are known to play a significant role in the immune response. Fibrinogen is a protein that plays a crucial role in blood clotting (often found at the dermal-epidermal junction). These deposits cause vascular thickening, which is a hallmark of NL.

== Natural occurrence == Accurate measurements, beginning in the early 1970s, appeared to detect primordial plutonium-244, making it the shortest-lived primordial nuclide. As the age of the Earth is about 56 half-lives of 244Pu, the amount of 244Pu left should be very small; Hoffman et al. estimated its content in the rare-earth mineral bastnasite as c244 = 1.0×10−18 g/g, which corresponded to the content in the Earth crust as low as 3×10−25 g/g (i.e. the total mass of plutonium-244 in Earth's crust is about 9 g). Since 244Pu cannot be easily produced by natural neutron capture in the low neutron activity environment of uranium ores (see below), its presence cannot plausibly be explained by any other means than creation by r-process nucleosynthesis in supernovae or neutron star mergers. However, the detection of primordial 244Pu in 1971 is not confirmed by recent, more sensitive measurements using accelerator mass spectrometry. In a 2012 study, no traces of 244Pu in the samples of bastnasite (taken from the same mine as in the early study) were observed, so only an upper limit on the 244Pu content was obtained: c244 < 1.5×10−19 g/g: 370 (or fewer) atoms per gram of the sample, at least seven times lower than the abundance measured by Hoffman et al. A 2022 study, once again using accelerator mass spectrometry, could not detect 244Pu in Bayan Obo bastnasite, finding an upper limit of < 2.1×10−20 g/g (about seven times lower than the 2012 study). Thus, the 1971 detection cannot have been a signal of primordial 244Pu.

== Legality == The legality of AI-generated pornography remains an evolving issue. In some countries, laws concerning digital simulation may apply indirectly, particularly when the generated content features images of real people without their consent. Additionally, most existing laws regulate deepfake pornography of nonconsenting individuals, rather than fully synthesized AI pornography.

Sources: en.wikipedia.org

Notes from published material

Evidence from the study of the pelvis and hindlimbs of Cyonasua, indicative of morphological similarities to bones of scansorial and terrestrial generalist carnivorans such as members of the genera Galictis, Meles and Arctictis, is presented by Tarquini et al. (2026). Tseng (2026) describes the first known partial skeleton of Leptarctus wortmani from the Hemphillian strata from the Rome Beds (Oregon, United States), providing evidence of morphology of the postcranial skeleton similar to those of extant badgers belonging to the genus Meles. Lopatin et al. (2026) describe a molar of a member of the genus Mellivora from the Pleistocene strata from the Tham Hai Cave, representing the first known record of Mellivorinae in Southeast Asia. A new specimen of Cernictis hesperus, providing new information on the anatomy of members of this species, is described from the (probably late Hemphillian) strata of the Pinole Tuff Formation (California, United States) by Tseng (2026). A well-preserved cranium of a Pleistocene sable is described from the Ogorokha Site (Sakha Republic, Russia) by Boeskorov et al. (2026). Sotnikova et al. (2026) report the discovery of new fossil material of large-bodied wolverines from the Pleistocene strata from the Indigirka River basin and New Siberia (Sakha Republic, Russia), and interpret their large size as likely to be physiological adaptation to the mammoth steppe environment. Rule et al.

Stiffness in connective tissue made of high amounts of collagen Environmental factors such as a lack of mobility, fitness, and activity Lack of movement by a fetus in the womb (leading to arthrogryposis and fetal hypomobility syndrome) Taut (tensely pulled) soft tissue, bony obstructions, and jammed meniscoid bodies (fibrous, fatty tissues found in joints) in the spine While environmental factors can contribute to hypomobility, it also has a genetic component. The genes that contain the instructions for making the proteins, which are used to make the connective tissue throughout the body, are passed on from parents to their offspring. If the instructions cause collagen proteins to be numerous and highly condensed, the connective tissue will be firmer. If collagen is more spread out and produced at a smaller frequency, the connective tissue will be softer. On the other hand, the protein elastin has the opposite effect on the flexibility of connective tissue, with more elastin causing the tissue to be softer and more fluid-like. The softer the connective tissue, the more innate flexibility an individual has compared to those around them with firmer connective tissue, and the opposite is true if an individual has firmer tissue. Several issues in utero can cause hypomobility and other similar conditions to develop later on in life. The development of various skeletal disorders can lead to joint hypomobility as an infant develops.

=== Liver === As a meal containing carbohydrates or protein is eaten and digested, blood glucose levels rise, and the pancreas secretes insulin. Blood glucose from the portal vein enters liver cells (hepatocytes). Insulin acts on the hepatocytes to stimulate the action of several enzymes, including glycogen synthase. Glucose molecules are added to the chains of glycogen as long as both insulin and glucose remain plentiful. In this postprandial or "fed" state, the liver takes in more glucose from the blood than it releases. After a meal has been digested and glucose levels begin to fall, insulin secretion is reduced, and glycogen synthesis stops. When it is needed for energy, glycogen is broken down and converted again to glucose. Glycogen phosphorylase is the primary enzyme of glycogen breakdown. For the next 8–12 hours, glucose derived from liver glycogen is the primary source of blood glucose used by the rest of the body for fuel. Glucagon, another hormone produced by the pancreas, in many respects serves as a countersignal to insulin. In response to insulin levels being below normal (when blood levels of glucose begin to fall below the normal range), glucagon is secreted in increasing amounts and stimulates both glycogenolysis (the breakdown of glycogen) and gluconeogenesis (the production of glucose from other sources).

== Other systems == Member of Parliament can be the term (often a translation) for representatives in parliamentary democracies that do not follow the Westminster system and who are usually referred to in a different fashion, such as deputé in France, deputato in Italy, deputat in Bulgaria, parlamentario or diputado in Spain and Spanish-speaking Latin America, deputado in Portugal and Brazil, and Mitglied des Bundestages (MdB) in Germany. However, better translations are often possible.

Thus, although E2 causes genetic changes conducive to its own inactivation, the decrease in estrogenic activity yields a toxicologically active metabolite that constitutes an additional pathway of estradiol-dependent carcinogenesis. 4-OH-E2 shares the metabolic scheme of 2-OH-E2: methylation to 4-methoxyestradiol (4-meOE2), oxidation to quinones, or dehydrogenation to 4-OH-E1. Conjugation by the ubiquitously present COMT represents the most common extrahepatic pathway of 4-OH-E2 inactivation. However, if estrogen homeostasis is imbalanced by an increase in CYP1B1 and a decrease in COMT, a greater degree of genotoxic quinone formation from 4-OH-E2 will occur. 4-OHE2 can be oxidized by microsomal CYPs or peroxidases to yield estradiol-3,4-semiquinone. This semiquinone can undergo redox cycling with oxygen to form estradiol-3,4-quinone (E2-3,4-Q) and superoxide. E2-3,4-Q can be converted back to 4-OHE2 in a single step by quinone reductase, or in two sequential steps catalysed by P450 reductase via the semiquinone intermediate. GSH / S-transferase activity can abrogate E2-3,4-Q levels via formation of glutathione conjugates. E2-3,4-Q is a potent nucleophile, and will readily react with electrophilic DNA. This yields the formation of the DNA adducts 4-OHE2-1-N7Gua and 4-OHE2-1-N3Ade via a Michael addition. Destabilization of the glycosyl bond between the nitrogenous base and ribose sugar creates apurinic sites as the unstable adducts are lost from DNA. 4-OHE2-1-N7Gua has a relatively slow depurination half-life of approx.

Sources: en.wikipedia.org

Frequently asked questions